Last reviewed · How we verify
BERBERINE
At a glance
| Generic name | BERBERINE |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Berberine Phytosome for Signs and Symptoms of Polycystic Ovary Syndrome (PCOS) (NA)
- Berberine Supplementation, Sprint Interval Training, and Immune Function Study (NA)
- 30 Day Insulin Balance Metabolic Health Optimization Protocol (NA)
- A Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes (NA)
- Effects of Akkermansia Muciniphila and Berberine Supplementation on Insulin Sensitivity in Night-shift Workers (NA)
- Evaluation of the Synergistic Effect of Combining a Prebiotic and a Postbiotic on Intestinal Discomfort (NA)
- Berberine in Treating Negative Symptoms of Schizophrenia: Clinical Efficacy and Mechanisms (NA)
- Berberine Improving Cognitive Impairments in Schizophrenia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BERBERINE CI brief — competitive landscape report
- BERBERINE updates RSS · CI watch RSS